Adam Maeder Analyst PerformanceResearch Analyst at Piper SandlerAdam Maeder is a stock analyst at Piper Sandler in the healthcare sector, covering 15 publicly traded companies. Over the past year, Adam Maeder has issued 39 stock ratings, including buy and hold recommendations. While full access to Adam Maeder's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Adam Maeder's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings73 Last 6 YearsBuy Recommendations73.13% 49 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution67RatingsDistribution of strong buy, buy, hold, and sell ratings by Adam Maeder.RatingPercentageCount Strong Buy0.0%0 ratings Buy73.1%49 ratings Hold26.9%18 ratings Sell0.0%0 ratingsOut of 67 total stock ratings issued by Adam Maeder at Piper Sandler, the majority (73.1%) have been Buy recommendations, followed by 26.9% Hold.Best & Worst CallsBest Call0000.0%INSPSep 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TCMDNov 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNYSE46.7% of companies on NYSE7 companiesNASDAQ46.7% of companies on NASDAQ7 companiesNYSEAMERICAN6.7% of companies on NYSEAMERICAN1 companyAdam Maeder, an analyst at Piper Sandler, currently covers 15 companies listed on NYSE, NASDAQ and NYSEAMERICAN, with the majority traded on NYSE.Coverage FocusSector IconSectorPercentageHealthcare15 companies100.0%Adam Maeder of Piper Sandler specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageHEALTHCARE EQUIPMENT & SUPPLIES15 companies100.0% About Adam MaederAdam Maeder is a managing director and senior research analyst focused on the medical technology sector. Prior to joining Piper Sandler in 2019, Maeder worked in medical technology equity research at Wells Fargo Securities. Additionally, he worked at Westwicke Partners providing investor relations strategy and capital markets advisory to medical technology and diagnostics companies. Maeder began his career working on the equity capital markets desk at Piper Sandler. Maeder holds a BBA in finance from the University of Iowa.Follow on LinkedIn Adam Maeder's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRMDResMed8/7/2026Lower Price Target$209.58$225.00Neutral$0.0000.00% ROINYXHNyxoah8/6/2026Reiterated Rating$1.33$6.00Overweight$0.0000.00% ROIINSPInspire Medical Systems8/4/2026Boost Price Target$52.22$60.00Neutral$0.0000.00% ROIGKOSGlaukos7/30/2026Reiterated Rating$161.97$195.00Overweight$0.0000.00% ROIISRGIntuitive Surgical7/27/2026Set Price Target$356.58$357.44$0.0000.00% ROIEWEdwards Lifesciences7/24/2026Reiterated Rating$83.63$101.00Overweight$0.0000.00% ROIISRGIntuitive Surgical7/17/2026Reiterated Rating$402.33$470.00Overweight$0.0000.00% ROIABTAbbott Laboratories7/17/2026Reiterated Rating$99.70$118.00Overweight$0.0000.00% ROIGKOSGlaukos7/1/2026Reiterated Rating$140.00$165.00Overweight$0.0000.00% ROIABTAbbott Laboratories6/22/2026Reiterated Rating$88.14$115.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ISRGIntuitive Surgical6/2/2026Reiterated Rating$397.16$580.00Overweight$0.0000.00% ROISTAASTAAR Surgical5/14/2026Boost Price Target$29.40$33.00Neutral$0.0000.00% ROINYXHNyxoah5/13/2026Reiterated Rating$3.07$7.00Overweight$0.0000.00% ROISTXSStereotaxis5/13/2026Reiterated Rating$1.92$3.50Overweight$0.0000.00% ROINSPRInspireMD5/5/2026Reiterated Rating$1.17$3.00Overweight$0.0000.00% ROIINSPInspire Medical Systems5/5/2026Downgrade$54.77$55.00Neutral$0.0000.00% ROIISRGIntuitive Surgical4/22/2026Lower Price Target$451.29$580.00Overweight$0.0000.00% ROIABTAbbott Laboratories4/17/2026Lower Price Target$95.08$115.00Overweight$0.0000.00% ROIRXSTRxSight2/26/2026Lower Price Target$7.44$10.00Neutral$0.0000.00% ROILIVNLivaNova2/19/2026Reiterated Rating$67.26$85.00Overweight$0.0000.00% ROITCMDTactile Systems Technology2/18/2026Boost Price Target$28.05$42.00Overweight$0.0000.00% ROIINSPInspire Medical Systems2/12/2026Lower Price Target$68.50$85.00Overweight$0.0000.00% ROIEWEdwards Lifesciences2/11/2026Reiterated Rating$77.00$100.00Overweight$0.0000.00% ROIRMDResMed1/30/2026Boost Price Target$257.83$275.00Neutral$0.0000.00% ROIISRGIntuitive Surgical1/23/2026Reiterated Rating$525.81$620.00Overweight$0.0000.00% ROIABTAbbott Laboratories1/23/2026Lower Price Target$108.50$135.00Overweight$0.0000.00% ROIRXSTRxSight1/20/2026Boost Price Target$9.81$11.00Neutral$0.0000.00% ROIEWEdwards Lifesciences1/20/2026Reiterated Rating$84.39$98.00Overweight$0.0000.00% ROITCMDTactile Systems Technology1/5/2026Set Price Target$27.40$35.00$0.0000.00% ROITCMDTactile Systems Technology1/5/2026Upgrade$27.40$35.00Overweight$0.0000.00% ROISGHTSight Sciences1/5/2026Upgrade$7.48$9.00Overweight$0.0000.00% ROIINSPInspire Medical Systems12/8/2025Boost Price Target$136.75$165.00Overweight$0.0000.00% ROINYXHNyxoah11/14/2025Reiterated Rating$5.31$9.00Overweight$0.0000.00% ROISGHTSight Sciences11/7/2025Boost Price Target$5.00$5.00Neutral$0.0000.00% ROITCMDTactile Systems Technology11/4/2025Reiterated Rating$21.77$20.00Neutral$0.0000.00% ROIINSPInspire Medical Systems11/4/2025Reiterated Rating$85.03$135.00Overweight$0.0000.00% ROIEWEdwards Lifesciences10/31/2025Reiterated Rating$84.09$95.00Overweight$0.0000.00% ROIISRGIntuitive Surgical10/22/2025Boost Price Target$462.74$610.00Overweight$0.0000.00% ROIRBOTVicarious Surgical8/13/2025Lower Price Target$9.25$7.00Neutral$0.0000.00% ROIINSPInspire Medical Systems8/5/2025Lower Price Target$130.79$150.00Overweight$00.0000.00% ROIThey didn't warn anyone in 1971. This time someone is warning you. (Ad)On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.Request the free guide in 30 seconds and get positioned nowRMDResMed8/1/2025Boost Price Target$272.16$270.00Neutral$000.0000.00% ROIEWEdwards Lifesciences7/25/2025Boost Price Target$79.41$90.00Overweight$00.0000.00% ROIISRGIntuitive Surgical7/23/2025Reiterated Rating$496.23$595.00Overweight$000.0000.00% ROINSPRInspireMD5/12/2025Lower Price Target$2.54$4.00Overweight$0.0000.00% ROITCMDTactile Systems Technology5/6/2025Downgrade$13.94$14.00Neutral$00.0000.00% ROIEWEdwards Lifesciences4/24/2025Upgrade$70.33$80.00Overweight$00.0000.00% ROIISRGIntuitive Surgical4/23/2025Lower Price Target$492.31$575.00Overweight$000.0000.00% ROIABTAbbott Laboratories4/17/2025Reiterated Rating$131.84$145.00Overweight$00.0000.00% ROIRXSTRxSight4/15/2025Initiated Coverage$14.42$18.00Neutral$0.0000.00% ROIRBOTVicarious Surgical3/18/2025Lower Price Target$9.10$8.50Neutral$0.0000.00% ROIEWEdwards Lifesciences2/12/2025Boost Price Target$75.47$73.00Neutral$00.0000.00% ROIINSPInspire Medical Systems2/10/2025Lower Price Target$182.00$233.00Overweight$00.0000.00% ROIISRGIntuitive Surgical1/24/2025Reiterated Rating$587.08$670.00Overweight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
